Comunicati Stampa
Salute e Benessere

Zero Candida Applies to List its Shares on the TSX Venture Exchange

Immediately following the completion of the Acquisition, the following persons were appointed as directors of the Company: Immediately following the completion of the Acquisition, the following persons were appointed as directors of the Company: Eli Ben-HarooshAsher Holzer Orit Berger Christina Cameron Also, immediately following the completion of the Acquisition, the following persons were appointed as officers of the Company: Eli Ben-Haroosh, Chief Executive OfficerSophya...
VANCOUVER, BC, (informazione.it - comunicati stampa - salute e benessere)

Immediately following the completion of the Acquisition, the following persons were appointed as directors of the Company:

Eli Ben-Haroosh
Asher Holzer
Orit Berger
Christina Cameron

Also, immediately following the completion of the Acquisition, the following persons were appointed as officers of the Company:

Eli Ben-Haroosh, Chief Executive Officer
Sophya Galper-Komet , Chief Financial Officer and Corporate Secretary

"Our new technology that will be a game changer in the field of women's health in the world. The company is advancing in its research with the hope of involving hospitals and academic institutions around the world. Our company's vision is to complete a pre-clinical study by 6/2025 and submit it to the FDA. The company continues to develop a final prototype for human use and will complete it by Q1 2025."

"Zero Candida has a potential to become a technological leader and use its ground-breaking technology to expand boundaries of non-chemical candida treatment,"

The listing of the Common Shares on the TSXV remains subject to the review of the TSXV and is contingent on the satisfaction of all listing and regulatory requirements. There is no assurance that the TSXV will approve the listing application or that the Company will complete the listing on the TSXV as currently proposed.

Subject to the final TSXV approval, the Common Shares are expected to commence trading on or about November 25, 2024 .

ZC is a private Israeli company that was formed to commercially exploit a number of patents and patent applications with respect to an AI smart tampon-like device, designed to treat Candidiasis and transfer the medical information via Wi-Fi to the doctor. ZC technology is a combination of a therapy light source with a selected wavelength and intensity and a transparent gel-based drug delivery system to maintain the optimum Ph level in the vagina. The device when used overnight, demonstrated a 99.9999% Candidiasis elimination in the vagina within 3 nights.

ZC developed a first prototype of its device in May of 2022 and immediately commenced its first laboratory tests as a "proof of concept".  In September 2023 ZC completed its pre-clinical animal studies and subsequently developed a protype (1st series) and commenced its validation. ZC is currently in the process of developing the design of its device and continues pre-clinical animal studies. ZC expects to pursue "Fast Track" approval with the FDA as a Class II De Novo device.

In May 2024 , ZC received a report with respect to its pre-clinical safety study, that indicated no abnormal findings in gross-pathology and histopathology and identified no safety concerns with respect to ZC blue light illumination device.

On behalf of the Board of Directors
Eli Ben-Haroosh, CEO
For further information please contact
Mr. Eli Ban-Haroosh at eli@zero-candida.com ;  972—51-565-2355

NO SECURITIES REGULATORY AUTHORITY HAS EITHER APPROVED OR DISAPPROVED OF THE CONTENTS OF THIS RELEASE. NEITHER THE TSXV NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSXV) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

THIS PRESS RELEASE, REQUIRED BY APPLICABLE CANADIAN LAWS IS NOT FOR DISTRIBUTION TO U.S. NEWS SERVICES OR FOR DISSEMINATION IN THE UNITED STATES , AND DOES NOT CONSTITUTE AN OFFER TO SELL OR SOLICITATION OF AN OFFER TO SELL ANY OF THE SECURITIES DESCRIBED HEREIN IN THE UNITED STATES , THESE SECURITIES HAVE NOT BEEN, AND WILL NOT BE, REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1993, AS AMENDED, OR ANY SECURITIES LAWS, AND MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES OR U.S. PERSONS UNLESS REGISTERED OR EXEMPT THEREFROM.

View original content: https://www.prnewswire.co.uk/news-releases/zero-candida-applies-to-list-its-shares-on-the-tsx-venture-exchange-302308286.html

Ufficio Stampa
 PR Newswire (Leggi tutti i comunicati)
209 - 215 Blackfriars Road
LONDON United Kingdom
Allegati
Non disponibili